Halogen atoms in the modern medicinal chemistry: hints for the drug design.

A significant number of drugs and drug candidates in clinical development are halogenated structures. For a long time, insertion of halogen atoms on hit or lead compounds was predominantly performed to exploit their steric effects, through the ability of these bulk atoms to occupy the binding site of molecular targets. However, halogens in drug - target complexes influence several processes rather than steric aspects alone. For example, the formation of halogen bonds in ligand-target complexes is now recognized as a kind of intermolecular interaction that favorably contributes to the stability of ligand-target complexes. This paper is aimed at introducing the fascinating versatility of halogen atoms. It starts summarizing the prevalence of halogenated drugs and their structural and pharmacological features. Next, we discuss the identification and prediction of halogen bonds in protein-ligand complexes, and how these bonds should be exploited. Interesting results of halogen insertions during the processes of hit-to-lead or lead-to-drug conversions are also detailed. Polyhalogenated anesthetics and protein kinase inhibitors that bear halogens are analyzed as cases studies. Thereby, this review serves as one guide for the virtual screening of libraries containing halogenated compounds and may be a source of inspiration for the medicinal chemists.

[1]  M. Shimaoka,et al.  Crystal structure of isoflurane bound to integrin LFA‐1 supports a unified mechanism of volatile anesthetic action in the immune and central nervous systems , 2009, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  Gianni Chessari,et al.  From fragment to clinical candidate--a historical perspective. , 2009, Drug discovery today.

[3]  Jennifer M. Adler,et al.  Crystal Structure of Iodotyrosine Deiodinase, a Novel Flavoprotein Responsible for Iodide Salvage in Thyroid Glands* , 2009, The Journal of Biological Chemistry.

[4]  Nahid M. Yazdani,et al.  Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. , 2009, Journal of medicinal chemistry.

[5]  Yong-Jun Jiang,et al.  Ab initio calculations on halogen‐bonded complexes and comparison with density functional methods , 2009, J. Comput. Chem..

[6]  Zhihai Liu,et al.  Comparative Assessment of Scoring Functions on a Diverse Test Set , 2009, J. Chem. Inf. Model..

[7]  Stefan Güssregen,et al.  Evidence for C-Cl/C-Br...pi interactions as an important contribution to protein-ligand binding affinity. , 2009, Angewandte Chemie.

[8]  Yiannis N Kaznessis,et al.  Path-integral method for predicting relative binding affinities of protein-ligand complexes. , 2009, Journal of the American Chemical Society.

[9]  D. Herschlag,et al.  Evaluating the potential for halogen bonding in the oxyanion hole of ketosteroid isomerase using unnatural amino acid mutagenesis. , 2009, ACS chemical biology.

[10]  Jean-Luc Wolfender,et al.  Modern approaches in the search for new lead antiparasitic compounds from higher plants. , 2009, Current drug targets.

[11]  R. D. dos Santos,et al.  Early toxicity screening and selection of lead compounds for parasitic diseases. , 2009, Current drug targets.

[12]  Ettore Novellino,et al.  Exploiting the pyrazolo[3,4-d]pyrimidin-4-one ring system as a useful template to obtain potent adenosine deaminase inhibitors. , 2009, Journal of medicinal chemistry.

[13]  Brian W Matthews,et al.  Halogenated benzenes bound within a non-polar cavity in T4 lysozyme provide examples of I...S and I...Se halogen-bonding. , 2009, Journal of molecular biology.

[14]  G. Candiani,et al.  Assessing the Bioisosterism of the Trifluoromethyl Group with a Protease Probe , 2009, ChemMedChem.

[15]  F. Diederich,et al.  Pentafluorosulfanyl as a Novel Building Block for Enzyme Inhibitors: Trypanothione Reductase Inhibition and Antiprotozoal Activities of Diarylamines , 2009, Chembiochem : a European journal of chemical biology.

[16]  Jongki Hong,et al.  Cytotoxic bromotyrosine derivatives from a two-sponge association of Jaspis sp. and Poecillastra sp. , 2008, Bioorganic & medicinal chemistry letters.

[17]  M. Shimaoka,et al.  The volatile anesthetic isoflurane perturbs conformational activation of integrin LFA‐1 by binding to the allosteric regulatory cavity , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Adnan Memic,et al.  How Do Halogen Substituents Contribute to Protein‐Binding Interactions? A Thermodynamic Study of Peptide Ligands with Diverse Aryl Halides , 2008, Chembiochem : a European journal of chemical biology.

[19]  P. Metrangolo,et al.  Halogen Versus Hydrogen , 2008, Science.

[20]  Pierangelo Metrangolo,et al.  Halogen bonding in supramolecular chemistry. , 2008, Angewandte Chemie.

[21]  Adrian Whitty,et al.  Cooperativity and biological complexity. , 2008, Nature chemical biology.

[22]  W. Hagmann,et al.  The many roles for fluorine in medicinal chemistry. , 2008, Journal of medicinal chemistry.

[23]  Vladimir V Poroikov,et al.  Computer-aided discovery of anti-inflammatory thiazolidinones with dual cyclooxygenase/lipoxygenase inhibition. , 2008, Journal of medicinal chemistry.

[24]  Jan Schultz,et al.  Integration of fragment screening and library design. , 2007, Drug discovery today.

[25]  Y. Shishido,et al.  Synthesis of aromatic compounds containing a 1,1-dialkyl-2-trifluoromethyl group, a bioisostere of the tert-alkyl moiety. , 2007, Bioorganic & medicinal chemistry letters.

[26]  M. Soares,et al.  Synthesis, Cruzain Docking, and in vitro Studies of Aryl‐4‐Oxothiazolylhydrazones Against Trypanosoma cruzi , 2007, ChemMedChem.

[27]  P Voth Regier Andrea and Ho Shing,et al.  The role of halogen bonding in inhibitor recognition and binding by protein kinases. , 2007 .

[28]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[29]  Peter Politzer,et al.  Molecular surface electrostatic potentials and anesthetic activity , 2007, Journal of molecular modeling.

[30]  G. V. Paolini,et al.  Global mapping of pharmacological space , 2006, Nature Biotechnology.

[31]  G. Klebe Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.

[32]  Hisayoshi Kobayashi,et al.  Diastereomers of dibromo-7-epi-10-deacetylcephalomannine: crowded and cytotoxic taxanes exhibit halogen bonds. , 2006, Journal of medicinal chemistry.

[33]  S. Wonnacott,et al.  From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research. , 2005, Drug discovery today.

[34]  Christophe Meyer,et al.  Crystal structures for HIV-1 reverse transcriptase in complexes with three pyridinone derivatives: a new class of non-nucleoside inhibitors effective against a broad range of drug-resistant strains. , 2005, Journal of medicinal chemistry.

[35]  B. Orser,et al.  Emerging molecular mechanisms of general anesthetic action. , 2005, Trends in pharmacological sciences.

[36]  Pierangelo Metrangolo,et al.  Halogen bonding based recognition processes: a world parallel to hydrogen bonding. , 2005, Accounts of chemical research.

[37]  Jin Kwan Kim,et al.  Biarylcarboxybenzamide derivatives as potent vanilloid receptor (VR1) antagonistic ligands. , 2005, Bioorganic & medicinal chemistry letters.

[38]  Eric Westhof,et al.  Halogen bonds in biological molecules. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[39]  Kelly Chibale,et al.  Synthesis and structure-activity relationships of parasiticidal thiosemicarbazone cysteine protease inhibitors against Plasmodium falciparum, Trypanosoma brucei, and Trypanosoma cruzi. , 2004, Journal of medicinal chemistry.

[40]  Grégori Gerebtzoff,et al.  Halogenation of Drugs Enhances Membrane Binding and Permeation , 2004, Chembiochem : a European journal of chemical biology.

[41]  Justin C. Biffinger,et al.  The Polar Hydrophobicity of Fluorinated Compounds , 2004, Chembiochem : a European journal of chemical biology.

[42]  Dmytro M. Havaleshko,et al.  Isoflurane Pretreatment Supports Hemodynamics and Leukocyte Rolling Velocities in Rat Mesentery During Lipopolysaccharide-Induced Inflammation , 2004, Anesthesia and analgesia.

[43]  M. Berthelot,et al.  Halogen-bond geometry: a crystallographic database investigation of dihalogen complexes. , 2003, Acta crystallographica. Section B, Structural science.

[44]  H. Kubinyi Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[45]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[46]  A. Gołębiowski,et al.  Lead compounds discovered from libraries: part 2. , 2003, Current opinion in chemical biology.

[47]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[48]  F. Canduri,et al.  Molecular model of cyclin-dependent kinase 5 complexed with roscovitine. , 2002, Biochemical and biophysical research communications.

[49]  Y. Martin,et al.  Do structurally similar molecules have similar biological activity? , 2002, Journal of medicinal chemistry.

[50]  Stephen R. Johnson,et al.  Molecular properties that influence the oral bioavailability of drug candidates. , 2002, Journal of medicinal chemistry.

[51]  W. F. de Azevedo,et al.  Structural basis for inhibition of cyclin-dependent kinase 9 by flavopiridol. , 2002, Biochemical and biophysical research communications.

[52]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[53]  P. Metrangolo,et al.  Halogen bonding: a paradigm in supramolecular chemistry. , 2001, Chemistry.

[54]  P. Wardman Electron transfer and oxidative stress as key factors in the design of drugs selectively active in hypoxia. , 2001, Current medicinal chemistry.

[55]  E. Eger,et al.  Neither GABAA nor Strychnine-Sensitive Glycine Receptors Are the Sole Mediators of MAC for Isoflurane , 2001, Anesthesia and analgesia.

[56]  M Pastor,et al.  VolSurf: a new tool for the pharmacokinetic optimization of lead compounds. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[57]  P. Selzer,et al.  Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. , 2000, Journal of medicinal chemistry.

[58]  V. Hruby,et al.  The effect of halogenation on blood–brain barrier permeability of a novel peptide drug☆ , 1999, Peptides.

[59]  John M. Barnard,et al.  Chemical Similarity Searching , 1998, J. Chem. Inf. Comput. Sci..

[60]  E. Sausville,et al.  Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity In vivo against human leukemia and lymphoma xenografts. , 1998, Blood.

[61]  E. Eger,et al.  Minimum Alveolar Anesthetic Concentration Values for the Enantiomers of Isoflurane Differ Minimally , 1997, Anesthesia and analgesia.

[62]  Robin Taylor,et al.  Hydrogen bonding of carbonyl, ether, and ester oxygen atoms with alkanol hydroxyl groups , 1997, J. Comput. Chem..

[63]  J. Tocher Reductive activation of nitroheterocyclic compounds. , 1997, General pharmacology.

[64]  H. Maehr Combinatorial chemistry in drug research from a new vantage point. , 1997, Bioorganic & medicinal chemistry.

[65]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[66]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[67]  Frank H. Allen,et al.  The Nature and Geometry of Intermolecular Interactions between Halogens and Oxygen or Nitrogen , 1996 .

[68]  S H Kim,et al.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[69]  L. Povirk,et al.  DNA damage and mutagenesis induced by nitrogen mustards. , 1994, Mutation research.

[70]  R. Dickinson,et al.  Can the stereoselective effects of the anesthetic isoflurane be accounted for by lipid solubility? , 1994, Biophysical journal.

[71]  T. Connick,et al.  Fluorine-19 nuclear magnetic resonance studies of binary and ternary complexes of thymidylate synthase utilizing a fluorine-labeled folate analogue. , 1993, Biochemistry.

[72]  W. R. Lieb,et al.  Stereospecific effects of inhalational general anesthetic optical isomers on nerve ion channels. , 1991, Science.

[73]  J. Rossjohn,et al.  The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. , 2006, Blood.

[74]  L. M. Lima,et al.  Bioisosterism: a useful strategy for molecular modification and drug design. , 2005, Current medicinal chemistry.

[75]  N. Hrib The dopamine D4 receptor: A controversial therapeutic target , 2000 .

[76]  M. Schlosser,et al.  About the “physiological size” of fluorine substituents: Comparison of sensorially active compounds with fluorine and methyl substituted analogues , 1996 .